NeuroProfile seals licence agreement with Henkel
The company NeuroProfile, founded in 2001 from the psychiatric department at the district clinic in Regensburg, works on the identification of disease relevant genes and proteins, which play a role in Alzheimer’s, Parkinson’s, schizophrenia and depression. NeuroProfile’s core activities are in research, development and marketing of therapeutic target molecules, so-called “drug targets” (starting points for new medicines), to be able to develop on this basis new medicines for diseases of the central nervous system. Ever increasing neurodegenerative disease seen with increased age cannot be currently cured. The company has been able to develop several successful projects in the field of tissue engineering in the manufacture of nervous tissue. These can be cultivated on the basis of acquired neuronal stem cells and serve currently as the best possible cellular model for the analysis in the so-called “validation” (testing) of drug targets. Neuroprofile has now licensed out this process to Henkel, the leading company in the field of “white biotechnology“. Henkel with 55,000 employees worldwide is active in the market for laundry and cleaning agents, cosmetics and personal hygiene and also adhesive technologies (e.g. adhesives). The licence grants the company Henkel non-exclusive right of use of the tissue cultivation for its research and development.
For more information see: